Aprea Therapeutics (NASDAQ:APRE – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Aprea Therapeutics to post earnings of ($0.69) per share and revenue of $0.15 million for the quarter.
Aprea Therapeutics Stock Down 1.2 %
Shares of APRE stock opened at $2.39 on Friday. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $6.80. The company has a market capitalization of $12.99 million, a price-to-earnings ratio of -0.85 and a beta of 0.82. The firm has a fifty day moving average of $3.18 and a 200-day moving average of $3.27.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- How to Short Nasdaq: An Easy-to-Follow Guide
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Do S&P 500 Stocks Tell Investors About the Market?
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
